Apollo to buy speciality pharmaceutical company Covis Pharma
Apollo Global Management has agreed to acquire the Netherlands-based speciality pharmaceutical company Covis Pharma from Cerberus Capital Management for an undisclosed sum.
Apollo Global Management has agreed to acquire the Netherlands-based speciality pharmaceutical company Covis Pharma from Cerberus Capital Management for an undisclosed sum.
Allergan has agreed to sell brazikumab (formerly MEDI2070) and Zenpep (pancrelipase) to AstraZeneca and Nestle, respectively, in separate deals, for an undisclosed price.
Atnahs Pharma has agreed to acquire hypertension medicines from AstraZeneca in a deal valued at around $390m.
Calidi Biotherapeutics, a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, announced Series A investments from two South Korean firms to advance manufacturing in preparation for Calidi's pre-IND and IND filings.
Eli Lilly is set to invest more than $470m to build a new pharmaceutical manufacturing facility in North Carolina, US.
The products are now a part of Armas' consistently growing product line, bringing their portfolio count to eleven
Bayer has entered into a licence agreement with Daré Bioscience to commercialise investigational contraceptive product called Ovaprene in the US.
Charles River Laboratories International has wrapped up its $380m acquisition of HemaCare, a California-based human-derived cellular products provider for the cell therapy market.
US-based Amgen has closed the acquisition of a 20.5% stake in Chinese biopharmaceutical firm BeiGene for approximately $2.8bn to support the expansion of its oncology footprint in China.
GlaxoSmithKline (GSK) has completed the sale of its travel vaccines Rabipur for rabies, and Encepur for tick-borne encephalitis, to Bavarian Nordic.